STERIS (STE) Stock Buyback History
TTM buyback yield 1.48% · Shareholder yield (TTM) 1.48%.
STE
TTM buyback yield
1.48%
Shareholder yield (TTM)
1.48%
5Y share count change
14.9%
TTM buyback spend
$321.10M
SBC coverage (TTM)
3.42x
YoY change in spend
+11.4%
5Y CAGR of spend
+74.3%
Peak year (2023)
$308.56M
Cumulative spend
$1.84B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- STERIS (STE) repurchased about $321.10M of stock over the trailing twelve months.
- Diluted share count is up 14.9% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 3.42× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +74.3% per year over the latest 5-year window.
- TTM repurchases used about 44% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2026 | $235.50M | $0.00 | $235.50M | 0.10B | -0.4% | 1.09% |
| 2025 | $211.32M | $57.40M | $153.92M | 0.10B | -0.3% | 0.95% |
| 2024 | $11.77M | $56.53M | −$44.77M | 0.10B | -0.9% | 0.05% |
| 2023 | $308.56M | $38.95M | $269.61M | 0.10B | 2.0% | 1.63% |
| 2022 | $55.78M | $57.66M | −$1.88M | 0.10B | 14.5% | 0.23% |
| 2021 | $14.65M | $25.97M | −$11.32M | 0.09B | 0.3% | 0.09% |
| 2020 | $51.24M | $23.81M | $27.43M | 0.09B | 0.2% | 0.43% |
| 2019 | $81.49M | $23.96M | $57.53M | 0.09B | -0.3% | 0.76% |
| 2018 | $65.48M | $22.19M | $43.30M | 0.09B | -0.4% | 0.83% |
| 2017 | $97.51M | $18.79M | $78.72M | 0.09B | 20.9% | 1.65% |
| 2016 | $14.37M | $16.15M | −$1.78M | 0.07B | 18.6% | 0.24% |
| 2015 | $30.69M | $14.92M | $15.77M | 0.06B | 0.5% | 0.73% |
| 2014 | $25.47M | $11.10M | $14.37M | 0.06B | 1.5% | 0.90% |
| 2013 | $8.00M | $8.92M | −$915.00K | 0.06B | -0.2% | 0.33% |
| 2012 | $56.75M | $7.86M | $48.89M | 0.06B | -2.0% | 3.11% |
| 2011 | $29.96M | $10.19M | $19.78M | 0.06B | 1.2% | 1.46% |
| 2010 | $310.00K | $7.37M | −$7.06M | 0.06B | -0.0% | 0.02% |
| 2009 | $80.47M | $7.37M | $73.10M | 0.06B | -7.5% | 5.91% |
| 2008 | $177.17M | $0.00 | $177.17M | 0.06B | -2.2% | 10.73% |
| 2007 | $60.17M | $0.00 | $60.17M | 0.07B | -4.6% | 3.51% |
| 2006 | $84.15M | $0.00 | $84.15M | 0.07B | -1.4% | 5.10% |
| 2005 | $33.87M | $0.00 | $33.87M | 0.07B | -1.4% | 1.93% |
| 2004 | $16.61M | $0.00 | $16.61M | 0.07B | -0.1% | 0.94% |
| 2003 | $16.07M | $0.00 | $16.07M | 0.07B | -0.2% | 0.89% |
| 2002 | $0.00 | $0.00 | $0.00 | 0.07B | 7.9% | — |
| 2001 | $0.00 | $0.00 | $0.00 | 0.07B | -5.8% | — |
| 2000 | $28.71M | $0.00 | $28.71M | 0.07B | -1.2% | — |
| 1999 | $17.70M | $0.00 | $17.70M | 0.07B | 2.8% | — |
| 1998 | $10.10M | $0.00 | $10.10M | 0.07B | 1.2% | — |
| 1997 | $11.40M | $0.00 | $11.40M | 0.07B | — | — |
| 1996 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for STERIS (STE) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for STERIS (STE)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for STERIS (STE)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2026 | $235.50M | +11.4% | +$24.18M | ||
| 2025 | $211.32M | +1696.2% | +$199.56M | ||
| 2024 | $11.77M | -96.2% | -$296.80M | ||
| 2023 | $308.56M | +453.2% | +$252.79M | ||
| 2022 | $55.78M | +280.8% | +$41.13M | ||
| 2021 | $14.65M | -71.4% | -$36.59M | ||
| 2020 | $51.24M | -37.1% | -$30.25M | ||
| 2019 | $81.49M | +24.4% | +$16.01M | ||
| 2018 | $65.48M | -32.8% | -$32.02M | ||
| 2017 | $97.51M | +578.6% | +$83.14M | ||
| 2016 | $14.37M | -53.2% | -$16.32M | ||
| 2015 | $30.69M | +20.5% | +$5.22M | ||
| 2014 | $25.47M | +218.3% | +$17.47M | ||
| 2013 | $8.00M | -85.9% | -$48.75M | ||
| 2012 | $56.75M | +89.4% | +$26.79M | ||
| 2011 | $29.96M | +9566.1% | +$29.66M | ||
| 2010 | $310,000 | -99.6% | -$80.16M | ||
| 2009 | $80.47M | -54.6% | -$96.70M | ||
| 2008 | $177.17M | +194.5% | +$117.00M | ||
| 2007 | $60.17M | -28.5% | -$23.98M | ||
| 2006 | $84.15M | +148.5% | +$50.28M | ||
| 2005 | $33.87M | +103.9% | +$17.26M | ||
| 2004 | $16.61M | +3.4% | +$539,000 | ||
| 2003 | $16.07M | — | +$16.07M | ||
| 2002 | $0 | — | $0 | ||
| 2001 | $0 | -100.0% | -$28.71M | ||
| 2000 | $28.71M | +62.2% | +$11.01M | ||
| 1999 | $17.70M | +75.2% | +$7.60M | ||
| 1998 | $10.10M | -11.4% | -$1.30M | ||
| 1997 | $11.40M | — | +$11.40M | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | — | $0 | ||
| 1993 | $0 | — | $0 | ||
| 1992 | $0 | — | $0 | ||
| 1991 | $0 | — | — |
As of the 2026 fiscal year, STERIS (STE) reported buyback spend of $235.50M – grew 11.4% year-over-year.
Through 2021–2026 (5 years), STERIS buyback spend delivered a +74.3% annualised rate; sustaining 2 straight years of year-over-year growth.
STERIS buyback spend peaked at $308.56M in 2023; the latest annual figure is $235.50M in 2026 (23.7% below peak).
Across the available history, buyback spend reached its high of $308.56M in 2023 and its low of $0 in 1991.
Within Healthcare, STERIS (STE) ranks 8th among 8 peers we track. The peer median for buyback spend is $2.75B.
STERIS Buyback Spend 2026: $235.50M
STERIS buyback spend in 2026 was $235.50M, grew 11.4% from 2025.
STERIS Buyback Spend 2025: $211.32M
STERIS buyback spend in 2025 was $211.32M, surged 1696.2% from 2024.
STERIS Buyback Spend 2024: $11.77M
STERIS buyback spend in 2024 was $11.77M, plunged 96.2% below 2023.
STERIS Buyback Spend 2023: $308.56M
STERIS buyback spend in 2023 was $308.56M, surged 453.2% from 2022. This figure represents the highest annual value in the available history.
STERIS Buyback Spend 2022: $55.78M
STERIS buyback spend in 2022 was $55.78M.
See more financial history for STERIS (STE).
Sector peers by buyback spend
Companies in the same sector as STERIS, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 3.42×.
Capital allocation mix
How STERIS splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $730.60M (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from STERIS's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does STERIS buy back its own stock?
Yes, STERIS (STE) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does STERIS spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $321.10M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is STERIS's buyback yield?
TTM buyback yield is about 1.48% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is STERIS's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 1.48% combined (TTM-based where available).
Is STERIS diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has STERIS's share count changed?
Diluted weighted average shares changed by about 14.9% over roughly five fiscal years (annual income statement data).
What is STERIS's buyback spend?
Latest reported buyback spend for STERIS (STE) is $321.10M (period ending March 31, 2026).
How has STERIS buyback spend changed year-over-year?
STERIS (STE) buyback spend changed +11.4% year-over-year on the latest annual filing.
What is the long-term growth rate of STERIS buyback spend?
STERIS (STE) buyback spend compound annual growth rate is +74.3% over the most recent 5 years available.
When did STERIS buyback spend hit its highest annual value?
STERIS buyback spend reached its highest annual value of $308.56M in 2023.
What was STERIS buyback spend in 2025?
STERIS (STE) buyback spend in 2025 was $211.32M.
What was STERIS buyback spend in 2026?
STERIS (STE) buyback spend in 2026 was $235.50M.
Explore more
STE Overview
Company profile, financial tools, and key metrics
STE Revenue Counter
Earns $188.23 every second. See per minute, hour, and day.
STE Earnings Counter
Earns $24.81 per second net profit. See per minute, hour, and day.
STE Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
STE What If Invested
What if you had invested $1,000? See historical returns from any date.
STE How It Makes Money
Discover visual breakdown of $5.94B in revenue — where it comes from and where it goes.
STE Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
STE Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
STE Daily Price Character
Balanced · 50.0% historical win rate (green days). Streaks & record days.
STE Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.
STE Dividend Profile
Yield: 1.14%. Safety: 7/7. See full history.
STE Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
STE Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
STE Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
STE Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.